A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in subjects 18 to 78 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-first)
The purpose of this study is to test how well the study medication, quizartinib, works when taken with standard chemotherapy to put AML into remission and then taken alone to prevent relapses of AML.
Primary Sponsor: Daiichi Sankyo Inc.
Prinicipal Investigator: Imad Tabbara, M.D./Medicine; Division of Hematology/Oncology
Contact Phone: 202-741-2981
Are you interested in more information on this clinical trial?